Announced Thu, 9 Jul · 10:49 IST
OneSource clarifies no material impact from DRL Semaglutide supply delay
Business Updates View source PDF
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1612.00
prior close
₹1652.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.1-0.1-0.5+1.2+3.7+2.2+1.5+2.3+4.5————
Up moveDown movePending
AI summary
OneSource Specialty Pharma clarified that Dr. Reddy's Laboratories delay in commercial supplies of Semaglutide will not have any material impact on its operations. The company said it has enough demand from other customers including Canada, with capacities fully committed. New capacity additions planned this quarter and later this year will allow OneSource to meet DRL's demand once DRL is ready to resume.
Likely market impact
Reassurance for investors: DRL's delay will not hurt OneSource's finances; demand and capacity remain strong.